Medivir continues extension study of MIV-711 in knee OA

An IDMC recommended continuation of a Phase IIa extension study of MIV-711 from Medivir AB (SSE:MVIR B) in 50 patients with moderate knee osteoarthritis (OA). The open-label, international extension is evaluating the safety of once-daily 200 mg MIV-711. Data are expected in 1H18...